Drug Profile
Research programme: antibody-drug conjugates - PolyTherics/Spirogen
Latest Information Update: 10 Aug 2021
Price :
$50
*
At a glance
- Originator PolyTherics; Spirogen
- Class Immunotoxins; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in United Kingdom (Parenteral)
- 15 Oct 2013 Spirogen has been acquired by MedImmune
- 04 Apr 2012 Early research in Cancer in United Kingdom (Parenteral)